What Are HIV Integrase Inhibitors and How Do They Work?

Integrase inhibitors have become the backbone of modern HIV treatment, recommended as first-line therapy by every major guideline body worldwide. These drugs block a step in the viral life cycle that older antiretrovirals leave untouched, and the practical result is faster viral suppression, fewer drug interactions, and a higher barrier to resistance than most alternatives. Their rise from a niche option in 2007 to the default choice in nearly every clinical setting tells a story about how a single mechanistic insight reshaped the management of a global pandemic.

How Integrase Inhibitors Work

HIV needs to weave a DNA copy of its genome into the chromosomes of your immune cells. The enzyme responsible for this step, called integrase, assembles into a large molecular machine known as an intasome, which physically cuts the host DNA and inserts the viral copy. Integrase strand transfer inhibitors, or INSTIs, jam this process by binding to metal ions in the enzyme’s active site right at the moment the viral DNA is about to be stitched in.¹ Without successful integration, HIV cannot establish a permanent foothold in the cell, and no new virus particles are produced from that infection event.²

Because integrase inhibitors act later in the viral life cycle than reverse transcriptase inhibitors or entry inhibitors, they produce a noticeably faster drop in the amount of virus in the blood after someone starts treatment. This is not because the drug is inherently “stronger” but because it blocks a step that happens closer to the end of the replication process, meaning fewer partially completed viral copies are still in the pipeline when the drug kicks in.³

The Drugs in the Class

Five INSTIs have reached the clinic, and they split naturally into two generations. The first generation includes raltegravir (approved 2007) and elvitegravir (approved 2012). Both work well, but they share a vulnerability: resistance mutations can knock them both out at the same time because they bind in a similar way. Elvitegravir also requires a pharmacokinetic booster called cobicistat, which introduces additional drug interactions.⁴

The second generation brought dolutegravir (2013), bictegravir (2018), and cabotegravir (2021). These drugs bind more tightly and dissociate more slowly from the integrase complex, which translates into a much higher barrier to resistance. In practice, this distinction matters enormously. Dolutegravir and bictegravir are now the most commonly prescribed antiretrovirals on the planet, and cabotegravir introduced something entirely new: a long-acting injectable formulation that replaces daily pills with shots every two months.

Speed and Depth of Viral Suppression

One of the clearest clinical advantages of integrase inhibitors is how quickly they drive viral load down to undetectable levels. A study in British Columbia found that people starting INSTI-based treatment reached viral suppression in an average of about 21 days, compared with roughly 59 days on non-INSTI regimens.⁵ Even among people who started treatment with very high viral loads, the gap persisted: about 35 days on an INSTI regimen versus 83 days without one. That speed matters not only for the individual’s health but also for reducing the window during which they can transmit HIV to others.

Real-world clinical data from a U.S. cohort showed a similar pattern. People on INSTI-based regimens had a median time to suppression of 60 days, compared with 137 days on non-nucleoside reverse transcriptase inhibitor regimens and 147 days on protease inhibitor regimens.⁶ The numbers vary between studies depending on how suppression is defined and measured, but the direction is consistent: INSTIs get the job done faster.

There is also emerging evidence that INSTIs push viral load lower than older drug classes, not just faster. One study found that switching from a protease inhibitor or non-nucleoside regimen to an INSTI-based regimen increased the rate of having truly undetectable virus (no target detected on sensitive assays) from about 53% to 92%.⁷ Whether this ultra-low-level suppression translates into better long-term health outcomes is still being studied, but it suggests that INSTIs are not just fast but thorough.

The Resistance Divide Between Generations

Resistance is where the two generations of integrase inhibitors diverge most sharply. Raltegravir and elvitegravir share three main resistance pathways, centered on mutations at positions 143, 148, and 155 in the integrase gene. The mutation at position 155 tends to appear first because it develops quickly, but the virus eventually shifts toward mutations at positions 148 or 143, which confer stronger resistance and restore the virus’s ability to replicate.⁸ Critically, resistance mutations at position 148 with certain secondary mutations cause cross-resistance to both raltegravir and elvitegravir, which means losing one drug often means losing both.⁹

In a study tracking patients on INSTI treatment, resistance mutations emerged in about 36% of those who experienced treatment failure, with the position-155 mutation appearing most frequently regardless of which first-generation INSTI was being used.¹⁰

Dolutegravir changed this picture dramatically. In pivotal trials enrolling over 1,100 treatment-naive patients, not a single person on dolutegravir developed resistance mutations in the integrase gene.¹¹ Laboratory studies confirmed why: even when researchers introduced the mutations that defeat raltegravir and elvitegravir, the virus still could not easily escape dolutegravir. The exception is mutations at position 148 combined with specific secondary changes, which can partially reduce dolutegravir’s effectiveness.¹² This high genetic barrier also holds when dolutegravir is used in simplified two-drug regimens.¹³

Side Effects Worth Knowing About

Integrase inhibitors are generally well tolerated, which is one reason they overtook older drug classes so quickly. But two side-effect patterns have drawn attention as real-world use expanded beyond the controlled populations of clinical trials.

The first is weight gain. People who switch to an INSTI-based regimen tend to put on more weight than those who stay on older drugs. One study found an average gain of about 2.5 kg over two years after switching, compared with 1.1 kg in a control group that stayed on non-INSTI therapy.¹⁴ Not all INSTIs appear equal in this regard. A cross-sectional study found that about 74% of people on bictegravir experienced weight gain after roughly a year of treatment, compared with 49% on dolutegravir and 30% on non-INSTI regimens.¹⁵ The mechanism is not fully understood, and some researchers suspect changes in the gut microbiome may play a role. For most people, the weight gain is modest, but for those already at metabolic risk, it warrants monitoring.

The second concern is neuropsychiatric effects. Insomnia is the most commonly reported symptom, followed by dizziness, anxiety, and difficulty concentrating. In clinical trials, these effects appeared at low and similar rates across all INSTIs. But in real-world cohorts involving thousands of patients, dolutegravir in particular led to discontinuation due to neuropsychiatric symptoms in about 3.5% of patients (with a range from roughly 1.4% to 7.2% across different countries).¹⁶ These rates are higher than what was seen in the original trials and sometimes higher than with other INSTIs, a discrepancy that likely reflects the broader range of people treated in routine care compared with carefully selected trial participants.¹⁷ Symptoms typically appear within the first few weeks and, for most people, either resolve or remain mild enough to manage.

Drug Interactions and Practical Pitfalls

Compared with protease inhibitors or elvitegravir (which needs its booster), the newer INSTIs have relatively clean drug-interaction profiles. Dolutegravir is processed mainly by a liver enzyme called UGT1A1, with a smaller contribution from CYP3A4; it does not meaningfully inhibit or boost other drugs.¹⁸ Bictegravir shares a similar metabolic profile. Cabotegravir is even simpler in this respect, showing no inhibition or induction of the major enzyme pathways in clinical testing.¹⁹

The one interaction that trips people up is with metal-containing supplements and antacids. Because INSTIs work by binding to magnesium ions inside the integrase enzyme, they are also attracted to calcium, magnesium, aluminum, and iron ions in the gut.²⁰ Taking an antacid or a mineral supplement too close to your INSTI dose can chelate the drug before it gets absorbed, slashing blood levels.²¹ The standard advice is to separate these products from your antiretroviral dose by at least two hours, though the exact guidance varies by drug. This is a surprisingly common cause of unexpectedly low drug levels, especially in people who take daily calcium or iron supplements without thinking about timing.

Simplified Regimens and Two-Drug Therapy

For decades, HIV treatment meant taking three active drugs. Dolutegravir’s high resistance barrier opened the door to trying something simpler: a two-drug regimen combining dolutegravir with just one other drug, lamivudine. The idea is to reduce the number of medications a person needs while maintaining full viral suppression and preserving future treatment options.

This approach has held up well. In real-world studies involving more than 100 patients per cohort, suppression rates at 48 weeks ranged from 97% to 100%, with virologic failure rates between 0% and about 3.3 per 100 person-years of follow-up. Only one case of emergent integrase resistance was reported, and that was in a person with a complex prior treatment history.²² The benefits are concrete: fewer pills, fewer potential toxicities from drugs you no longer need, and lower cost. A U.S. clinical care study confirmed that the results hold across age groups, sexes, and racial backgrounds.²³

Long-Acting Injectables

Cabotegravir paired with rilpivirine (a non-nucleoside reverse transcriptase inhibitor) became the first complete injectable HIV treatment regimen. Instead of daily pills, a healthcare provider gives two intramuscular injections every two months. In pooled results from two large trials, about 93% of people on the injectable regimen had undetectable viral loads at 48 weeks, compared with about 94% on daily oral therapy, meeting the statistical threshold for non-inferiority.²⁴ The earlier ATLAS trial individually confirmed a similar pattern, with about 92.5% of injectable recipients suppressed versus 95.5% on pills.²⁵

The appeal is obvious for people who struggle with daily adherence or who simply prefer not to take a pill every day. The trade-offs include injection-site reactions (common but usually mild), the need for regular clinic visits, and a narrow window if you miss an appointment: because the drug slowly releases from the injection site, a delayed visit can lead to sub-therapeutic levels and a risk of resistance.

Prevention with Cabotegravir

Cabotegravir’s long-acting properties also make it useful for pre-exposure prophylaxis, or PrEP, in people who do not have HIV. A pooled analysis of the major efficacy trials found that long-acting injectable cabotegravir reduced the risk of acquiring HIV by about 79% compared with daily oral PrEP.²⁶ That comparison is against an active control (daily tenofovir/emtricitabine), which is itself highly effective, so the absolute protection level is very high. Phase 2 data confirmed that dosing at eight-week intervals consistently delivers adequate drug concentrations in both men and women.²⁷

Cost is the main barrier to wide deployment. A modeling study in South Africa estimated that the price per injection would need to fall to roughly $9 to $14 for long-acting cabotegravir PrEP to be as cost-effective as daily oral PrEP from the government’s perspective.²⁸ Another analysis focused on adolescent girls and young women in South Africa found that at a drug price of about $65 per year, injectable PrEP would actually save money over a lifetime horizon.²⁹ Negotiations to bring generic versions to low-income countries are ongoing.

Pregnancy and Neural Tube Defect Concerns

In 2018, a surveillance study from Botswana flagged a possible link between dolutegravir taken around conception and neural tube defects in newborns. The updated data from that study found five neural tube defects among 1,683 deliveries where the mother was on dolutegravir at conception (about 0.30%), compared with a background rate of 0.08% in HIV-negative mothers and 0.10% in women on other antiretrovirals at conception.³⁰ Those numbers were small but statistically different, and they triggered restrictions on dolutegravir use in women of reproductive age for several years.

Subsequent, larger studies have been reassuring. A U.S. national cohort study using data from 2008 to 2020 found no significant difference in neural tube defect risk between dolutegravir-exposed and non-dolutegravir-exposed pregnancies, with only one case in the dolutegravir group.³¹ A Canadian surveillance study of 80 first-trimester dolutegravir exposures found four congenital anomalies, but none were neural tube defects.³² Most guidelines now permit dolutegravir for women of childbearing potential, with counseling about the low but uncertain residual risk. The Botswana signal has not disappeared, but its magnitude looks much smaller than initially feared, and the benefits of dolutegravir’s superior efficacy and resistance barrier are considerable for women who may have limited treatment options.

Children and Adolescents

Both raltegravir and dolutegravir have pediatric formulations, including chewable tablets and weight-based dosing schedules for children as young as four weeks old in some formulations. In adolescents, dolutegravir achieved drug levels comparable to adults when dosed at 50 mg once daily. At 48 weeks, about 74% of treatment-experienced adolescents reached a viral load below 400 copies per milliliter, and 61% reached below 50 copies. The drug was well tolerated, with no serious adverse events or discontinuations reported.³³ For younger children who cannot swallow tablets, raltegravir is available as a chewable tablet dosed by weight.³⁴

Global Rollout in Low- and Middle-Income Countries

The World Health Organization recommended dolutegravir-based regimens as preferred first-line therapy in 2018, and the transition in low- and middle-income countries has been swift. A survey of 175 HIV care clinics across 35 countries found that 90% had rolled out dolutegravir for first-line treatment, while 59% had also adopted it for second-line use. Every clinic in the highest-prevalence and lowest-income settings reported first-line rollout.³⁵

A systematic review and meta-analysis of programmatic data from these settings confirmed that adults retained in care on dolutegravir-based first-line treatment achieved viral suppression rates of 95% or higher for up to two years, meeting the UNAIDS target.³⁶ This is a meaningful achievement because real-world suppression rates in resource-limited settings had historically lagged behind trial results. Dolutegravir’s high resistance barrier means that even imperfect adherence is less likely to breed drug-resistant virus, which has enormous implications for public health in settings where second-line options are expensive and difficult to access.

Allosteric Integrase Inhibitors on the Horizon

All current integrase inhibitors work by blocking the enzyme’s active site, the spot where the actual DNA-cutting chemistry happens. A new class of drugs under development takes a different approach entirely: allosteric integrase inhibitors, or ALLINIs, bind at a separate site on the enzyme and disrupt its function through a different mechanism. Rather than blocking the DNA-insertion reaction directly, these compounds cause the integrase protein to clump together abnormally, which prevents it from interacting properly with viral RNA and leads to defective, non-infectious virus particles.³⁷

Because ALLINIs attack a completely different binding site, they remain active against viruses that carry resistance mutations to current INSTIs. One leading candidate, pirmitegravir, has entered phase 2a clinical trials.³⁸ Researchers have described the mechanism as “multimodal” because these drugs simultaneously block multiple functions of the enzyme, which may raise the genetic barrier to resistance even further.³⁹ If the clinical trials pan out, ALLINIs could become a valuable addition for people who have exhausted current INSTI options or a component of future long-acting combination injectables.

What Integrase Inhibitors Cannot Do to the Reservoir

One hope when integrase inhibitors were first introduced was that blocking a later step in the viral life cycle might shrink the reservoir of latently infected cells, the long-lived immune cells that harbor dormant HIV DNA and make the virus impossible to fully eradicate. That hope has not panned out. A randomized study comparing a raltegravir-based regimen to an efavirenz-based regimen found no difference in the rate at which viral DNA or RNA declined in lymph node tissue over time.⁴⁰ A separate trial that switched patients from a protease inhibitor regimen to dolutegravir found no change in the HIV reservoir measured in blood or in gut tissue biopsy samples.⁴¹

Integrase inhibitors are better at keeping the virus silent while someone takes them. They are not better at flushing dormant virus out of its hiding places. That distinction matters for cure research, where the reservoir remains the central obstacle, and no drug class approved so far has cracked it.

Future Long-Acting Treatment Combinations

The success of injectable cabotegravir plus rilpivirine has opened up interest in even more durable long-acting treatment options. A modeling study explored the potential of pairing cabotegravir with lenacapavir (a capsid inhibitor given every six months) as an all-injectable treatment regimen in African settings. The analysis estimated that if the combination could be sourced for around $80 per year, it would be cost-effective across a majority of modeled scenarios in Eastern, Central, Southern, and West Africa, averting an estimated 1,060 disability-adjusted life-years per year over 50 years.⁴² The trajectory is clear: the field is moving toward regimens that demand less of the person taking them, with integrase inhibitors at the center of nearly every combination under study.